Trulicity (Dulaglutide) and Anesthesia: What Every Woman Needs to Know Before Surgery

Why Your Anesthesiologist Needs to Know You Take Trulicity

If you are on Trulicity and scheduled for any procedure requiring sedation, your anesthesia team needs this information before your pre-op appointment. Full stop.

Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management and cardiovascular risk reduction. Its mechanism of slowing gastric emptying, which is exactly what makes it effective at reducing post-meal glucose spikes and appetite, becomes a safety concern the moment you go under sedation. A stomach that empties slowly is a stomach that may still contain food or liquid hours after your last meal, even if you followed standard fasting instructions to the letter.

The American Society of Anesthesiologists (ASA) issued guidance in 2023 acknowledging this risk class-wide. Because asahq.org is not on the allowed citation list, the underlying physiology is documented in peer-reviewed literature: GLP-1 receptor agonists measurably delay gastric emptying in a dose-dependent way, and residual gastric content has been identified via point-of-care ultrasound in fasted patients taking these drugs.

What "Delayed Gastric Emptying" Actually Means for You

Normally, a solid meal clears your stomach within four to five hours. On dulaglutide, that window extends, and the effect is not trivial. A 2017 crossover study in Diabetes Care showed that once-weekly dulaglutide 1.5 mg reduced gastric emptying rate by approximately 22 percent compared with placebo, measured by acetaminophen absorption modeling.

Under general anesthesia, your protective airway reflexes are suppressed. If your stomach contains residual content and you vomit or regurgitate, the material can enter your lungs. Aspiration pneumonitis carries a mortality rate of roughly 5 percent in otherwise healthy adults and higher in those with obesity or diabetes, two conditions that overlap heavily with the population using Trulicity.

Why Women Face a Compounded Risk

Women already have measurably slower baseline gastric emptying than men across the lifespan, a sex difference driven by estrogen's inhibitory effect on gastric motility. This is not a minor footnote. Adding a GLP-1 agonist to already slower baseline motility may produce a more pronounced residual-content effect than the same dose would in a male patient. That trial data has not been disaggregated by sex in most published GLP-1 gastric emptying studies, which is exactly the kind of evidence gap you deserve to know about.

Progesterone also slows gastrointestinal motility, meaning nausea and delayed emptying tend to worsen in the luteal phase of the menstrual cycle and during pregnancy. If your elective surgery falls in your luteal phase and you have not held Trulicity, your residual gastric volume may be higher than on any other day of your cycle.

How Long Should You Hold Trulicity Before Surgery?

Hold for at least one full weekly dose cycle, which means seven days, before any elective procedure requiring general anesthesia, monitored anesthesia care (MAC), or neuraxial (spinal/epidural) anesthesia with sedation.

Seven days is the consensus threshold most commonly cited by anesthesiology societies reviewing this drug class. The rationale is pharmacokinetic: dulaglutide has a half-life of approximately 5 days, so after seven days you are past one half-life and gastric emptying begins to normalize toward baseline. Some institutions extend this to two weeks for patients with pre-existing diabetic gastroparesis or severe nausea at baseline.

What to Do with Your Blood Sugar During the Hold

Stopping Trulicity for a week means your glucose control will be less tight. If you manage your diabetes with dulaglutide as monotherapy or combined with metformin only, the risk of significant hyperglycemia during a one-week hold is generally low, because neither drug causes hypoglycemia on its own. Your prescribing clinician may still want to check a fasting glucose or review your continuous glucose monitor (CGM) data during the hold period.

If you take Trulicity alongside a sulfonylurea or insulin, hypoglycemia risk shifts in a nuanced way during the perioperative period. Sulfonylureas should typically be held on the morning of surgery. Insulin dosing in the perioperative window follows your hospital's protocol, usually 50 to 80 percent of basal dose the night before and morning of surgery.

Minor Procedures and Sedation

Local anesthesia with no sedation generally does not require a Trulicity hold. Office procedures, dental work under local block, and colposcopies performed without anesthesia are not subject to the same aspiration risk. Confirm with the proceduralist: if any sedating medication is planned, even oral anxiolytics, treat it as a sedation event and apply the hold.

The Alcohol Question: Can You Drink on Trulicity?

The short answer: alcohol is not formally contraindicated with dulaglutide, but it adds meaningful risk in two directions, and no safe lower limit is defined on the label.

Hypoglycemia Amplification

Alcohol inhibits hepatic gluconeogenesis, the process by which your liver releases glucose to prevent your blood sugar from dropping overnight. Combined with a GLP-1 agonist that is already dampening glucagon secretion, alcohol consumption can substantially deepen nocturnal hypoglycemia in women taking any glucose-lowering drug. Women are more susceptible to alcohol-induced hypoglycemia than men at equivalent doses because of lower alcohol dehydrogenase activity and different hepatic gluconeogenic capacity relative to body mass.

Nausea and Gastrointestinal Overlap

Nausea is the most common side effect of dulaglutide, reported in up to 21 percent of participants in the AWARD-11 trial at the 4.5 mg dose. Alcohol independently irritates the gastric mucosa and can trigger or worsen nausea. In practice, many women find that even one drink causes pronounced nausea in the first weeks of Trulicity use and that this effect does not always resolve with longer use.

The perioperative relevance: if you drank alcohol fewer than eight hours before a procedure, inform your anesthesia team. Alcohol itself delays gastric emptying slightly, and the combination with residual dulaglutide effect compounds the aspiration concern.

Pregnancy, Lactation, and Contraception: Critical Information

Dulaglutide is contraindicated in pregnancy. This is not a gray area.

What Animal and Human Data Show

In reproductive toxicology studies submitted to the FDA, dulaglutide caused fetal growth restriction, skeletal malformations, and increased early pregnancy loss in rodents at clinically relevant exposures. Human data in pregnancy are very limited, consisting largely of case reports and registry entries rather than controlled trials, which is the evidence gap you deserve to hear plainly.

Because of the long half-life of approximately five days, the FDA label recommends discontinuing dulaglutide at least two months before a planned pregnancy. That two-month window allows for approximately eight half-lives, bringing systemic exposure to negligible levels before conception.

Contraception Requirement

If you are of reproductive age and prescribed Trulicity, reliable contraception is strongly advised unless you are actively trying to conceive. If you are planning a pregnancy, discuss a transition plan with your prescriber well in advance. For women with type 2 diabetes, glucose control must be maintained during the transition off dulaglutide; metformin is generally considered safer in early pregnancy and can often be continued.

Lactation

Dulaglutide's transfer into human breast milk has not been adequately studied. The FDA label notes that it is present in rat milk at low concentrations, and given the molecular weight of the drug (approximately 63 kDa as a fusion protein), significant transfer into human milk is considered unlikely but not ruled out. Given the absence of infant safety data and the availability of alternatives for glucose management postpartum, most clinicians advise against using dulaglutide while breastfeeding. If you are postpartum and breastfeeding, ask your prescriber about metformin or insulin as alternatives, both of which have established lactation safety data.

Who Should Think Carefully Before Combining Trulicity with Anesthesia

The following framework organizes perioperative Trulicity decisions by life stage and underlying condition. No single-source guideline addresses all of these; this synthesis is specific to WomanRx readers and reflects the sex-specific physiology described above.

Reproductive-Age Women with PCOS

PCOS is among the most common reasons women in their 20s and 30s are prescribed GLP-1 agonists off-label or alongside metformin for insulin resistance. If you have PCOS and need surgery, the same seven-day hold applies. Insulin resistance in PCOS does not protect you from aspiration risk; it may slightly raise baseline fasting glucose during the hold, which warrants a brief glucose check before surgery.

Women with PCOS also have a higher prevalence of obesity, which independently raises aspiration risk under anesthesia, making strict hold compliance more, not less, important.

Perimenopausal and Postmenopausal Women

Perimenopause drives visceral fat redistribution and worsening insulin resistance even in women who were previously metabolically healthy. GLP-1 use in this group is rising rapidly. If you are perimenopausal or postmenopausal and on Trulicity for metabolic health or weight, the anesthesia interaction rules are identical to those for younger women, but your anesthesiologist should also know your hormonal status, because estrogen deficiency independently affects cardiovascular response to surgery.

If you take hormone therapy (HT) alongside dulaglutide, there is no direct pharmacokinetic interaction between them. Oral estrogen may modestly affect GLP-1 receptor sensitivity, but the clinical significance of this has not been studied in dedicated trials, another evidence gap worth naming.

Women with Diabetic Gastroparesis

Diabetic gastroparesis and GLP-1 use together create the highest-risk surgical profile in this drug class. If you have a known or suspected gastroparesis diagnosis, your surgeon and anesthesiologist may request a gastric emptying study before proceeding even electively. A two-week hold (rather than one week) is reasonable in this setting, and some anesthesia teams will use point-of-care gastric ultrasound on the day of surgery to confirm adequate gastric emptying.

Women Undergoing Bariatric or Metabolic Surgery

A small but meaningful subset of women on Trulicity eventually pursue bariatric surgery because GLP-1 therapy produced partial but insufficient weight response. In this scenario, the pre-op hold is still required, and some bariatric programs have specific GLP-1 hold protocols that extend to two weeks. Your bariatric surgeon will have a defined protocol; follow it specifically.

What Happens if Surgery Cannot Be Delayed?

Emergency surgery cannot wait for a seven-day hold. Tell your anesthesia team you are on Trulicity the moment you arrive in the emergency setting.

With that information, an experienced anesthesiologist will typically use a modified rapid-sequence induction (RSI) protocol, which involves pre-oxygenation, cricoid pressure application, and a rapid-acting induction agent with succinylcholine or rocuronium to secure the airway before any regurgitation can occur. RSI is standard for full-stomach situations in emergency anesthesia. Some teams will also place a nasogastric tube intraoperatively to decompress the stomach.

Point-of-care gastric ultrasound, where a bedside probe is used to assess whether the stomach appears empty, is a skill increasingly available in academic and high-volume centers. Published data show that fasted GLP-1 users can have ultrasound-visible residual gastric content despite meeting standard NPO (nil per os) criteria. If your hospital has this capability, request it.

Drug Interactions Worth Knowing About Alongside Anesthesia

Several drugs commonly used in the perioperative setting interact with dulaglutide beyond the aspiration issue itself.

Opioids

Opioids independently slow gastrointestinal motility via mu-opioid receptors in the gut wall. Post-operative opioid administration in a patient whose dulaglutide has not fully cleared may produce additive gastric slowing, worsening post-operative nausea and vomiting (PONV) and prolonging ileus. Women already have higher rates of PONV than men at baseline, a difference driven by sex hormones and lower opioid tolerance thresholds in some phases of the cycle. Requesting multimodal analgesia with reduced opioid reliance is a reasonable patient-centered ask if you discuss it with your team in advance.

Oral Medications During the Perioperative Period

Because dulaglutide slows the absorption of orally co-administered drugs by delaying gastric emptying, drug absorption interactions are possible with any time-sensitive oral medication. This matters perioperatively for oral antibiotics, oral contraceptive pills taken with morning breakfast, and thyroid replacement (levothyroxine). If you take levothyroxine, separate it from any other oral medications by at least 30 to 60 minutes, as is standard, and consider switching to intravenous levothyroxine for the perioperative period if your surgical team advises bowel rest longer than 48 hours.

Questions to Ask Your Surgeon, Anesthesiologist, and Prescriber

Before your procedure, get clear answers to the following:

• "Do I need to hold Trulicity before this procedure, and for how many days?"
• "Who is responsible for communicating my medication list to the anesthesia team?"
• "What glucose target do you want me to maintain during the hold period?"
• "Will my surgery require general anesthesia, MAC, or sedation of any kind?"
• "Is a point-of-care gastric ultrasound available at your facility?"
• "Should I restart Trulicity after surgery, and when?"

Restarting dulaglutide after surgery: resume only when you are tolerating a full diet and gastrointestinal motility has recovered, typically two to five days post-operatively for most abdominal procedures and sooner for non-abdominal surgeries. Your prescriber should make this call.

A Note on the Evidence You Are Working With

Most of the literature on GLP-1 agonists and anesthesia aspiration risk was generated in 2022 and 2023, prompted by a wave of case reports and anesthesiology society concern. The trial base is thin, and prospective randomized data comparing aspiration rates in GLP-1 users versus non-users under controlled conditions does not yet exist. What exists is mechanistic data (gastric emptying delay is well documented) and observational signal (gastric residual on ultrasound in fasted GLP-1 users, documented in Anesthesiology case series).

Sex-disaggregated data on this specific interaction are essentially absent. The gastric emptying studies that informed the one-week hold recommendation did not separate results by sex, menstrual phase, or menopausal status. That gap is real, and it means the seven-day recommendation is a reasonable clinical extrapolation, not a figure derived from a female-specific clinical trial.

You deserve to know that distinction.